Literature DB >> 32682567

Modular, Circuit-Based Interventions Rescue Hippocampal-Dependent Social and Spatial Memory in a 22q11.2 Deletion Syndrome Mouse Model.

Julia B Kahn1, Russell G Port2, Stewart A Anderson2, Douglas A Coulter3.   

Abstract

BACKGROUND: 22q11.2 deletion syndrome (22qDS) manifests with myriad symptoms, including multiple neuropsychiatric disorders. Complications associated with the polygenic haploinsufficiency make 22qDS symptoms particularly difficult to manage with traditional therapeutic approaches. However, the varying mechanistic consequences often culminate to generate inappropriate regulation of neuronal circuit activity. We explored whether managing this aberrant activity in adults could be a therapeutically beneficial strategy.
METHODS: To assess and dissect hippocampal circuit function, we performed functional imaging in acute slices and targeted eloquent circuits (specific subcircuits tied to specific behavioral tasks) to provide relevant behavioral outputs. For example, the ventral and dorsal CA1 regions critically support social and spatial discrimination, respectively. We focally introduced chemogenetic constructs in 34 control and 24 22qDS model mice via adeno-associated viral vectors, driven by excitatory neuron-specific promoter elements, to manipulate circuit recruitment in an on-demand fashion.
RESULTS: 22qDS model mice exhibited CA1 excitatory ensemble hyperexcitability and concomitant behavioral deficits in both social and spatial memory. Remarkably, acute chemogenetic inhibition of pyramidal cells successfully corrected memory deficits and did so in a regionally specific manner: ventrally targeted constructs rescued only social behavior, while those expressed dorsally selectively affected spatial memory. Additionally, manipulating activity in control mice could recapitulate the memory deficits in a regionally specific manner.
CONCLUSIONS: These data suggest that retuning activity dysregulation can rescue function in disease-altered circuits, even in the face of a polygenetic haploinsufficiency with a strong developmental component. Targeting circuit excitability in a focal, modular manner may prove to be an effective therapeutic for treatment-resistant symptoms of mental illness.
Copyright © 2020 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  22q11.2 deletion syndrome; Chemogenetics; Circuit-based therapies; Hippocampus; Social memory; Spatial memory

Mesh:

Year:  2020        PMID: 32682567      PMCID: PMC7554065          DOI: 10.1016/j.biopsych.2020.04.028

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  51 in total

1.  Neurocognitive development in 22q11.2 deletion syndrome: comparison with youth having developmental delay and medical comorbidities.

Authors:  R E Gur; J J Yi; D M McDonald-McGinn; S X Tang; M E Calkins; D Whinna; M C Souders; A Savitt; E H Zackai; P J Moberg; B S Emanuel; R C Gur
Journal:  Mol Psychiatry       Date:  2014-01-21       Impact factor: 15.992

2.  Autism, ADHD, mental retardation and behavior problems in 100 individuals with 22q11 deletion syndrome.

Authors:  Lena Niklasson; Peder Rasmussen; Sólveig Oskarsdóttir; Christopher Gillberg
Journal:  Res Dev Disabil       Date:  2008-12-13

3.  α7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia.

Authors:  Gilda A Neves; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2018-04-19       Impact factor: 7.853

4.  Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11.2 deletion) syndrome.

Authors:  Tamar Green; Doron Gothelf; Bronwyn Glaser; Martin Debbane; Amos Frisch; Moshe Kotler; Abraham Weizman; Stephan Eliez
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-11       Impact factor: 8.829

5.  Hyperactivity and Reduced Activation of Anterior Hippocampus in Early Psychosis.

Authors:  Maureen McHugo; Pratik Talati; Kristan Armstrong; Simon N Vandekar; Jennifer Urbano Blackford; Neil D Woodward; Stephan Heckers
Journal:  Am J Psychiatry       Date:  2019-10-18       Impact factor: 18.112

6.  Positive psychotic symptoms are associated with divergent developmental trajectories of hippocampal volume during late adolescence in patients with 22q11DS.

Authors:  Valentina Mancini; Corrado Sandini; Maria C Padula; Daniela Zöller; Maude Schneider; Marie Schaer; Stephan Eliez
Journal:  Mol Psychiatry       Date:  2019-06-04       Impact factor: 15.992

7.  Ventral CA1 neurons store social memory.

Authors:  Teruhiro Okuyama; Takashi Kitamura; Dheeraj S Roy; Shigeyoshi Itohara; Susumu Tonegawa
Journal:  Science       Date:  2016-09-30       Impact factor: 47.728

8.  Clinical and cognitive risk factors for psychotic symptoms in 22q11.2 deletion syndrome: a transversal and longitudinal approach.

Authors:  Maude Schneider; Marie Schaer; A Kadir Mutlu; Sarah Menghetti; Bronwyn Glaser; Martin Debbané; Stephan Eliez
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-09-03       Impact factor: 4.785

9.  DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo.

Authors:  Karen J Thompson; Elham Khajehali; Sophie J Bradley; Jovana S Navarrete; Xi Ping Huang; Samuel Slocum; Jian Jin; Jing Liu; Yan Xiong; Reid H J Olsen; Jeffrey F Diberto; Kristen M Boyt; Melanie M Pina; Dipanwita Pati; Colin Molloy; Christoffer Bundgaard; Patrick M Sexton; Thomas L Kash; Michael J Krashes; Arthur Christopoulos; Bryan L Roth; Andrew B Tobin
Journal:  ACS Pharmacol Transl Sci       Date:  2018-07-27

10.  High-potency ligands for DREADD imaging and activation in rodents and monkeys.

Authors:  Jordi Bonaventura; Mark A G Eldridge; Feng Hu; Juan L Gomez; Marta Sanchez-Soto; Ara M Abramyan; Sherry Lam; Matthew A Boehm; Christina Ruiz; Mitchell R Farrell; Andrea Moreno; Islam Mustafa Galal Faress; Niels Andersen; John Y Lin; Ruin Moaddel; Patrick J Morris; Lei Shi; David R Sibley; Stephen V Mahler; Sadegh Nabavi; Martin G Pomper; Antonello Bonci; Andrew G Horti; Barry J Richmond; Michael Michaelides
Journal:  Nat Commun       Date:  2019-10-11       Impact factor: 14.919

View more
  4 in total

Review 1.  Chemogenetics as a neuromodulatory approach to treating neuropsychiatric diseases and disorders.

Authors:  Jingwei Song; Ruchit V Patel; Massoud Sharif; Anagha Ashokan; Michael Michaelides
Journal:  Mol Ther       Date:  2021-12-01       Impact factor: 11.454

2.  The 22q11.2 region regulates presynaptic gene-products linked to schizophrenia.

Authors:  Ralda Nehme; Olli Pietiläinen; Mykyta Artomov; Matthew Tegtmeyer; Vera Valakh; Leevi Lehtonen; Christina Bell; Tarjinder Singh; Aditi Trehan; John Sherwood; Danielle Manning; Emily Peirent; Rhea Malik; Ellen J Guss; Derek Hawes; Amanda Beccard; Anne M Bara; Dane Z Hazelbaker; Emanuela Zuccaro; Giulio Genovese; Alexander A Loboda; Anna Neumann; Christina Lilliehook; Outi Kuismin; Eija Hamalainen; Mitja Kurki; Christina M Hultman; Anna K Kähler; Joao A Paulo; Andrea Ganna; Jon Madison; Bruce Cohen; Donna McPhie; Rolf Adolfsson; Roy Perlis; Ricardo Dolmetsch; Samouil Farhi; Steven McCarroll; Steven Hyman; Ben Neale; Lindy E Barrett; Wade Harper; Aarno Palotie; Mark Daly; Kevin Eggan
Journal:  Nat Commun       Date:  2022-06-27       Impact factor: 17.694

3.  A novel role for the lateral habenula in fear learning.

Authors:  Tomas E Sachella; Marina R Ihidoype; Christophe D Proulx; Diego E Pafundo; Jorge H Medina; Pablo Mendez; Joaquin Piriz
Journal:  Neuropsychopharmacology       Date:  2022-02-25       Impact factor: 8.294

4.  Disruption of the blood-brain barrier in 22q11.2 deletion syndrome.

Authors:  Alexis M Crockett; Sean K Ryan; Adriana Hernandez Vásquez; Caroline Canning; Nickole Kanyuch; Hania Kebir; Guadalupe Ceja; James Gesualdi; Elaine Zackai; Donna McDonald-McGinn; Angela Viaene; Richa Kapoor; Naïl Benallegue; Raquel Gur; Stewart A Anderson; Jorge I Alvarez
Journal:  Brain       Date:  2021-06-22       Impact factor: 13.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.